TELA Bio, Inc. Net Change in Cash
TELA Bio, Inc. (TELA) reported Net Change in Cash of -$20.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$11.30M.
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$9.84M.
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$9.59M.
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$11.89M.
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$1.84M, a 130.97% decline from fiscal 2024.
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $5.94M, a 19.42% increase from fiscal 2023.
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $4.97M.
- TELA Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$1.91M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.47M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$11.30M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | -$1.84M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | -$22.97M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$17.69M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | -$9.84M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $5.94M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | -$29.43M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$20.23M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$9.59M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $4.97M 10-K · filed 2026-03-25 | |||
| 2023-09-30 | $16.18M 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | $23.25M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$11.89M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$1.91M 10-K · filed 2025-03-21 | |||
| 2022-09-30 | $10.29M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$16.21M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$10.91M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$30.46M 10-K · filed 2024-03-22 | |||
| 2021-09-30 | -$20.76M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$14.10M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$8.56M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $29.09M 10-K · filed 2023-03-23 | |||
| 2020-09-30 | $36.16M 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $40.17M 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | -$3.89M 10-Q · filed 2020-05-15 | |||
| 2019-12-31 | $28.02M 10-K · filed 2022-03-23 | |||
| 2019-09-30 | -$6.58M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$1.41M 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | -$7.85M 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $5.93M 10-K · filed 2021-03-25 | |||
| 2018-09-30 | -$9.43M 10-Q · filed 2019-12-18 | |||
| 2017-12-31 | $9.87M 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| InspireMD, Inc. (NSPR) | $0.033B |